Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer.
Yan Hiu Athena LeeJeffrey Shi Kai ChanChi Ho LeungAlex Qinyang LiuEdward Christopher DeeKenrick NgJohnathan ShamashGary TseDavid Ka Wai LeungChi-Fai NgPublished in: Cancer (2024)
Compared to abiraterone users, enzalutamide users have significantly lower risks of sepsis, pneumonia, cellulitis, or skin abscess.